Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and substitution of the depository's name as the registered owner.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has completed the acquisition of Group Pharmaceuticals' wellness portfolio, a strategic move to strengthen its wellness portfolio and create opportunities for cross-selling.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange about the transfer of shares to the Investor Education and Protection Fund (IEPF) and notice of loss of share certificate.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the allotment of 101825 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 2022.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, effective from October 01, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and six months ended September 30, 2026.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals has announced the acquisition of the Wellness Portfolio of Group Pharmaceuticals Limited for ₹23.7 crores, with additional consideration linked to FY 2027-28 sales, to strengthen its pharmaceutical portfolio and expand its market presence.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals has announced the acquisition of the Wellness Portfolio of Group Pharmaceuticals Limited, a move aimed at strengthening its presence in the pharmaceutical industry and expanding its product portfolio.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has submitted the Exchange a copy Scrutinizers report of Annual General Meeting held on September 18, 2026. Further, the company has informed the Exchange regarding voting results.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited held its 47th Annual General Meeting (AGM) on September 18, 2026, through video conferencing. The meeting adopted audited financial statements for FY 2026, declared a dividend, and appointed a new director. The company also ratified the remuneration of its cost auditors and approved the appointment of an independent director.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange about the publication of a newspaper advertisement regarding the Notice of 47th Annual General Meeting and E-Voting Information.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 18, 2026, along with the Annual Report for the FY 2025-26.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'providing a web-link of the Annual Report 2025-26 to members'. The company has issued letters to shareholders whose e-mail addresses are not registered with the Company/Depository Participants, providing the web-link along with the path to access the Annual Report 2025-26 including Notice of AGM of the Company on the Company's website.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Allotment of 27950 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022'.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange about a copy of newspaper publication regarding the 47th Annual General Meeting (AGM) of the company to be held on September 18, 2026, through Video Conferencing (VC) / Other Audio Visual Means (OAVM).

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has announced its Q1 FY27 earnings, reporting a 9% growth in sales and 21% growth in operating EBITDA and net profits. The company has also acquired a controlling stake in Aequitas Healthcare for Rs.25 crores and completed a Rs.40 crores share buyback.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has announced its Q1 FY27 earnings, with a 9% growth in sales and 21% growth in operating EBITDA and net profits. The company has also acquired a controlling stake in Aequitas Healthcare for Rs.25 crores and completed a Rs.40 crores share buyback.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has made available the audio recording of its Q1 FY27 Earnings Conference Call on its website, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication regarding Extract of Unaudited Financial Results for the quarter ended June 30, 2026.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange about change in Management, designating Mr. Balmukund Keshav as Deputy General Manager (Information Technology) and Mr. Sanjay Singhal as General Manager (CQA & Regulatory Affairs) effective July 29, 2026.

Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited has informed the Exchange about the grant of 1,20,000 employee stock options under Jagsonpal Pharmaceuticals Limited Employees Stock Option Plan, 2022.